Bullish indicating open at $55-$60, IPO prices at $37
Ironwood Pharmaceuticals , Inc. (NASDAQ:IRWD) stock has tumbled to a 52-week low, touching down at $1.42. This latest price level reflects a stark downturn for the company, which has seen its shares plummet by -83.69% over the past year. According to InvestingPro data, the stock’s RSI indicates oversold conditions, while analysts maintain price targets ranging from $3 to $14, suggesting potential recovery opportunities. Investors have been grappling with a challenging period for Ironwood, as the stock’s performance starkly contrasts with its previous market positions. The significant one-year change underlines the volatility and the pressures faced by the pharmaceutical industry, as well as company-specific factors that may have contributed to the decline. Despite the downturn, the company maintains strong liquidity with a current ratio of 4.66, and InvestingPro analysis indicates expected net income growth this year. As Ironwood’s stock hits this low threshold, market watchers and stakeholders are closely monitoring the company’s strategies and developments that might signal a turnaround or further distress in the coming months. For deeper insights, check out the comprehensive Pro Research Report available on InvestingPro, covering 1,400+ top stocks including IRWD.
In other recent news, Ironwood Pharmaceuticals reported its fourth-quarter earnings, revealing adjusted earnings per share of $0.02, which fell short of analyst estimates of $0.06. The company’s revenue for the quarter was $90.55 million, slightly below the expected $92.5 million. Despite the earnings miss, there was positive news regarding Ironwood’s pipeline drug, apraglutide, as the company initiated a rolling New Drug Application submission to the FDA, with completion anticipated by the third quarter of 2025. Additionally, data from an open-label extension study showed promising results for apraglutide, with more patients reducing reliance on parenteral support over time. Ironwood also reported an 11% year-over-year growth in prescription demand for its marketed drug Linzess for the full year 2024, although U.S. net sales of Linzess declined by 15% to $916.3 million compared to 2023. Looking forward, Ironwood provided 2025 revenue guidance of $260-290 million, while analysts had projected $287.6 million. The company anticipates Linzess U.S. net sales to be between $800-850 million in 2025. Ironwood concluded 2024 with $88.6 million in cash and cash equivalents, having generated $103.5 million in cash from operations for the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.